← Leaderboards
Ethan Perlstein
Maggie'S Pearl, Llc
$1,805,996
Attributed
$1,805,996
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $699.9K · FY2022–24$1M$750K$500K$250K$0
'22
'23
'24
Funding mix
By agency
NIH$1,805,996 · 1
By mechanism
R44$1,805,996 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Acetazolamide”
- Christopher Nikolaus Schmickl · University Of California, San Diego$690,340
- Benjamin Arthur Plog · Washington University$85,864
- Erika Beyrent · Pennsylvania State University, The$75,052
- Valentina Fokina Bryant · University Of Texas Med Br Galveston$24,526
Research focus
AcetazolamideAdultAdverse EffectsAdverse EventAffectAlanine TransaminaseAldehyde ReductaseAnimal ModelAntithrombin IiiAspartate TransaminaseAtaxiaCare ProvidersCaringCharcot-Marie-Tooth DiseaseChemistryChildChildhoodClimactericClinicClinical ResearchClinical TrialsCommercializationComplete Blood Count7 Year Old
Grant awards (3)
Targeting aldose reductase: A Phase IIb/III trial for the novel use of Epalrestat to treat Congenital Disorders of Glycosylation (PMM2-CDG)$553,056
R44 · FY2024 · DK · contact PI
Targeting aldose reductase: A Phase IIb/III trial for the novel use of Epalrestat to treat Congenital Disorders of Glycosylation (PMM2-CDG)$553,056
R44 · FY2023 · DK · contact PI
Targeting aldose reductase: A Phase IIb/III trial for the novel use of Epalrestat to treat Congenital Disorders of Glycosylation (PMM2-CDG)$699,884
R44 · FY2022 · DK · contact PI